Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist) monotherapy in patients with Wolfram syndrome type 1.
This research study is looking at a new medicine, called Mounjaro, for people who have Wolfram syndrome type 1. Wolfram syndrome is a rare condition. The main goal of this study is to see if Mounjaro can help people with the condition produce more C-peptide, a substance made by the body that is vital for controlling blood sugar levels. Scientists believe that increasing C-peptide might help manage some aspects of Wolfram syndrome. This is an early-stage study (Phase II), which means it's one of the first times this medicine is being tested in people with Wolfram syndrome to see if it's safe and shows promise. We want to find out if this treatment could eventually lead to more personalised care for those with the condition.
At a glance
What is this study about?
This study is about exploring a new treatment for people with a rare condition called Wolfram syndrome type 1. Wolfram syndrome is a serious, often life-long condition that can affect many parts of the body, including how your body handles sugar.
The medicine being tested is called Mounjaro. It's a type of medicine that works by helping your body release insulin and control blood sugar levels. Researchers want to see if Mounjaro can help people with Wolfram syndrome type 1 improve their body's ability to make C-peptide. C-peptide is a natural marker of how much insulin your body is producing, and insulin is really important for managing blood sugar. If Mounjaro can help increase C-peptide, it might mean it could be a useful way to help manage the condition.
This is an early study, known as Phase II. This means it's not yet known if the treatment works or how well it works. The aim is to gather important information to see if Mounjaro is a promising treatment for Wolfram syndrome type 1. This could be a step towards developing more tailored and effective treatments in the future.
Key takeaways
- This study is testing a new medicine called Mounjaro for Wolfram syndrome type 1.
- It aims to see if Mounjaro can help the body make more C-peptide, which is important for blood sugar control.
- This is an early-stage study (Phase II) to gather information on safety and effectiveness.
- Participation involves receiving injections of Mounjaro and attending regular clinic visits for health checks.
- The study is for adults aged 18 and over, both men and women.
- You can stop taking part in the study at any time.
Who may be eligible?
To join this study, you need to be an adult, aged 18 years or older. This study is open to both men and women.
There will be other specific rules about who can take part, which the study team will discuss with you. These rules are put in place to make sure the study is safe for participants and that the results are clear and useful.
It's important to remember that not everyone with Wolfram syndrome type 1 will be able to join. The study team will check your medical history and do some tests to see if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have Wolfram syndrome type 1?
- Are you able to attend regular clinic appointments?
- Are you able to receive injections of the study medicine?
What does participation involve?
If you decide to take part in this study, you would receive the study medicine, Mounjaro, as an injection. There are different strengths of the medicine (2.5 mg, 5 mg, or 7.5 mg), and the study team will decide which dose is appropriate for you. You would have regular appointments at the clinic for check-ups and assessments. These appointments would involve health checks, blood tests, and discussions about how you are feeling. One key assessment will be a special test called an MMTT (Mixed-Meal Tolerance Test), which measures your C-peptide levels over time after you've had a meal. The study team will tell you exactly how long you would be involved in the study, including the treatment period and follow-up visits. They will explain the full schedule of visits and what each visit would involve.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is Wolfram syndrome type 1?
Wolfram syndrome type 1 is a rare genetic condition that can affect several parts of the body, including how your body handles blood sugar.
What is C-peptide and why is it important?
C-peptide is a natural substance your body makes when it produces insulin. Insulin is vital for controlling blood sugar. Measuring C-peptide helps doctors understand how much insulin your body is making.
What is Mounjaro?
Mounjaro is a medicine being tested in this study. It's designed to help your body manage blood sugar levels.
Will I definitely get the active medicine if I join the study?
The study design will determine if everyone receives the active medicine. The study team will explain this to you clearly.
How long will the study last if I participate?
The full duration of your participation, including all visits and follow-ups, will be explained by the study team, as it varies depending on the study plan.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.